🇺🇸 FDA
Pipeline program

NKTR-262

17-262-01

Phase 2 small_molecule terminated

Quick answer

NKTR-262 for Melanoma is a Phase 2 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Melanoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials